Inflammatory response reduction

"Inflammatory response reduction" refers to the therapeutic strategy or physiological modulation aimed at controlling or decreasing the magnitude and duration of the inflammatory response in tissues. This multi-step process involves numerous cellular and molecular targets, including cytokines (TNF-α, IL-1, IL-6), their receptors (TNFR, IL-1R, IL-6R), and downstream signaling cascades (NF-κB, MAPK, JAK/STAT). The goal is to transition the immune system toward resolution, tissue healing, and restoration of homeostasis, avoiding tissue damage from chronic or excessive inflammation. Drugs achieving inflammation reduction act by blocking pro-inflammatory mediators, modulating immune cell phenotypes, or augmenting anti-inflammatory pathways. Because it describes a process, not a single molecule or receptor, "inflammatory response reduction" is not a canonical therapeutic target itself. This entry is best treated as a high-level functional category—therapeutic drugs and interventions would each be mapped to their specific molecular/target entities (e.g., "Tumor necrosis factor receptor", "Interleukin-6 receptor", "Nuclear factor kappa-B").

Other names

Resolution of inflammationAnti-inflammatory responseSuppression of inflammationModulation of inflammatory signaling

Inhibition of pro-inflammatory cytokine signaling (e.g., TNF, IL-1, IL-6 blocking); Modulation of transcription factors (NF-κB, JAK/STAT pathway inhibition); Promotion of anti-inflammatory cytokines (IL-10, TGF-β activity); Blockade of receptor activation (e.g., TLRs, cytokine receptors)